Detralex, 500 mg 30 pcs.

Pharmgroup:

Venotonizing and venoprotective agent.

Pharmacological action:

DETRALEX has venotonic and angioprotective properties.

The drug reduces venous distensibility and venous stasis, decreases capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to indicators of venous hemodynamics.

A statistically significant dose-dependent effect of DETRALEX was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 2 tablets.

DETRALEX increases venous tone: venous occlusion plethysmography showed a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders a statistically significant increase of capillary resistance evaluated by angiostereometry after DETRALEX therapy was observed compared to placebo.

Therapeutic effectiveness of DETRALEX has been proven in treatment of chronic diseases of lower limb veins and in treatment of hemorrhoids.

Pharmacokinetics:

The main excretion of the drug is in the feces. With the urine on average about 14% of the taken amount of the drug is excreted.

The elimination half-life is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Indications

Symptomatic treatment of venous-lymphatic insufficiency, feeling of heaviness in the legs, pain, “Morning fatigue” of the legs, cramps, trophic disorders, symptomatic treatment of exacerbation of hemorrhoids.

Pharmacological effect

Pharmaceutical group:

Venotonic and venoprotective agent.

Pharmaceutical action:

DETRALEX has venotonic and angioprotective properties.

The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics.

A statistically significant dose-dependent effect of the drug DETRALEX was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 2 tablets.

DETRALEX increases venous tone: using venous occlusion plethysmography, a decrease in the time of venous emptying was shown. In patients with signs of severe microcirculation disorders, there is a (statistically significant) increase in capillary resistance, assessed by angiostereometry, compared with placebo, after treatment with DETRALEX.

The therapeutic effectiveness of the drug DETRALEX has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Pharmacokinetics:

The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine.

The half-life is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Special instructions

In case of exacerbation of hemorrhoids, the administration of this drug does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the recommended periods. If symptoms do not disappear after short therapy, a proctological examination should be performed and the therapy reviewed.

In the presence of venous circulation disorders, the maximum effect of treatment is ensured by a combination with a healthy, well-balanced lifestyle, in which it is advisable to avoid long exposure to the sun, reduce body weight, take walks and, in some cases, wear special socks that improve blood circulation.

Impact on the ability to drive vehicles and operate machinery

The drug does not affect the ability to drive vehicles or perform work that requires a high speed of psychomotor reactions.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

1 tablet contains:

Active substances:

purified micronized flavonoid fraction 500 mg (including diosmin (90%) 450 mg,

flavonoids expressed as hesperidin (10%) 50 mg);

Excipients:

gelatin,

magnesium stearate,

microcrystalline cellulose,

sodium starch glycolate,

talc,

glycerol,

macrogol 6000,

hydroxypropyl methylcellulose,

iron oxide yellow (E172),

iron oxide red (E172),

titanium dioxide (E171),

sodium lauryl sulfate.

Pregnancy

Pregnancy

Experiments on animals did not reveal teratogenic effects.

To date, there have been no reports of any side effects when using the drug by pregnant women.

Breastfeeding

Due to the lack of data regarding the excretion of the drug into breast milk, taking the drug is not recommended for nursing women.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

From the side of the central nervous system: rarely – dizziness, headache, general malaise.

From the gastrointestinal tract: often – diarrhea, dyspepsia, nausea, vomiting; infrequently – colitis.

From the skin: rarely – rash, itching, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids. In exceptional cases – angioedema.

Storage conditions

No special storage conditions required

Shelf life

4 years

Manufacturer

Servier Rus LLC, Russia